This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

What Can We Learn From Recent Clinical Trials of Thrombolysis?

James Grotta, MD

Arch Neurol. 1996;53(10):1067-1070.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THIS PAST year has been particularly important for researchers and clinicians dedicated to acute stroke therapy. The publication of results from the first large randomized clinical trials of intravenous thrombolytic therapy^1,2 has finally demonstrated unequivocally that human ischemic stroke is a treatable disease. This momentous event has implications for all members of the stroke community, including patients, health care planners, and all clinical health professionals, especially neurologists and those involved in emergency patient care.

These results are also of critical interest to laboratory and clinical investigators. Over the past 5 years a healthy debate has developed in the stroke research community about the relevance of animal models to human stroke. The similarities and differences between stroke in patients vs rats, and between designing human clinical trials vs rodent experiments, have been discussed in detail^3-6 and do not need to be repeated here. What lessons can we learn from . . . [Full Text PDF of this Article]

Author Affiliations
From the Stroke Program, University of Texas Medical School at Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?